## DD: DuPont de Nemours, Inc. - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 2.6% below STRENGTH zone (3.0-6.0%); RSI 72 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (72).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($39.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. 429-room Hotel101 to rise in Milan Italy**
- Source: The Manila Times | 20251209T161008 | Somewhat-Bullish | Relevance: 98%
-  Hotel101 Global Holdings Corp., a Nasdaq-listed subsidiary of DoubleDragon Corporation, announced a joint venture to develop a 429-room Hotel101 in San Donato Milanese, Milan, Italy. This expansion introduces their "condotel" business model to the European market, strategically located near ENI headquarters and a major Italian motorway. The new hotel aims to cater to both leisure and business travelers, complementing existing accommodations in the area.

**2. Spotlight On Chemours’ Expansion Plans**
- Source: WilmingtonBiz | 20251210T141135 | Neutral | Relevance: 71%
- Local officials in Wilmington, New Hanover County, and the Cape Fear Public Utility Authority have unanimously opposed Chemours' plans to increase production at its Fayetteville plant, citing ongoing public health concerns related to PFAS chemicals and the company's historic lack of accountability. Despite Chemours' claims that upgrades would reduce PFAS emissions, critics remain skeptical, pointing to continued groundwater contamination and the significant costs incurred by the utility authority to filter out these "forever chemicals." The resolutions urge the state to prioritize public safety over increased production, highlighting the financial burden passed onto ratepayers.

**3. Scientists Say the Forever Chemical TFA Could Cause Irreversible Harm. In Eastern North Carolina, It’s Everywhere.**
- Source: Inside Climate News | 20251210T101135 | Neutral | Relevance: 71%
- A new study reveals high levels of the "forever chemical" TFA in blood and water samples in Eastern North Carolina, prompting concerns about its health impacts and Chemours' role in the pollution. The findings challenge industry assertions about TFA's benign nature and highlight the chemical's widespread environmental presence, leading to calls for stricter regulation and accountability. Local officials and environmental advocates are pushing back against Chemours' planned expansion of its Fayetteville Works plant, which is a source of other PFAS compounds that can break down into TFA.

**4. Top Companies in the Composite Resin Market- Ashland Inc.,**
- Source: openPR.com | 20251211T120900 | Somewhat-Bullish | Relevance: 64%
-  This article outlines the major companies dominating the composite resin market, including Ashland Inc., Huntsman Corporation, and BASF SE. It provides a strategic analysis of their approaches, a SWOT analysis of the market, and highlights emerging investment opportunities driven by innovation and sustainability goals across various sectors. The composite resin market is growing due to demand for high-performance materials in automotive, aerospace, and construction industries.

**5. Assessing Sherwin-Williams (SHW) Valuation After Its Recent Share Price Pullback**
- Source: Simply Wall Street | 20251209T123859 | Neutral | Relevance: 57%
- Sherwin-Williams (SHW) shares have recently pulled back, showing an 8.5% decline over 90 days, despite continued earnings and revenue growth. While a narrative-driven valuation suggests the stock is 15.4% undervalued with a fair value of $386.52, current market ratios indicate it's expensive at 31.4 times earnings compared to industry averages. This discrepancy prompts investors to consider whether the stock is an undervalued opportunity or if its premium is unsustainable.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-18 | RBC Capital | $48 | $100 | -52% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-18 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($0.27M) |
| Sells | 3 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+6.7%)
- Blackrock Inc.: 7.6% (-5.1%)
- State Street Corpora: 4.3% (-0.9%)
- Geode Capital Manage: 2.6% (+1.5%)
- Nuveen, LLC: 2.1% (+7.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +1.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Forward P/E 19.2x attractive for 25% earnings growth. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.4B |
| Beta | 1.14 |
| 52W Range | $22.50 - $41.80 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 19.2 |
| Current P/E | 24.0 |
| YoY Growth | 24.8% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from 1.1% to 2.6% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.4pp (needs >3.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.57% (CS: 65) | Neutral |
| RSI_14 | 71.9 | Overbought |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.130x | Above |
| vs SMA200 | 1.309x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $41.49
- **Stop Loss:** $39.57 (4.6% risk)
- **Target:** $43.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 718
- **Position Value:** $29,789.82
- **Portfolio %:** 29.79%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-10 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.98 | $1.09 | +11.2% |
| 2025Q2 | $1.06 | $1.12 | +5.5% |
| 2025Q1 | $0.95 | $1.03 | +8.1% |
| 2024Q4 | $0.98 | $1.13 | +15.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*